EZH2 Class Hit: ORIC Down After Tazverik Withdrawal

Oric Pharmaceuticals shares fell after Ipsen pulled Tazverik from all markets due to safety concerns in a key trial. Tazverik sales were already weak—a blow to confidence in similar EZH2 drugs like ORIC’s, even if they are not the same.